Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer.

ABSTRACT: Background and Objectives: In early-stage HER2-positive breast cancer, ado-trastuzumab emtansine (T-DM1) has been adopted as the preferred adjuvant approach for patients left with residual invasive disease despite neoadjuvant therapy. The influence of different neoadjuvant regimens on subsequent outcomes in real-world settings remains uncertain. Materials and Methods: From 2019 to 2025, 102 patients treated with adjuvant T-DM1 following surgery after neoadjuvant chemotherapy were retrospectively assessed. Neoadjuvant regimens included doxorubicin plus cyclophosphamide followed by trastuzumab-paclitaxel, doxorubicin plus cyclophosphamide with pertuzumab-trastuzumab-docetaxel, or docetaxel-carboplatin-trastuzumab-pertuzumab. Clinical features, treatment response, survival, and

SUBMITTER: Agaoglu AB 

PROVIDER: S-EPMC12654407 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature